Published in Breast Cancer Res on May 28, 2014
YC-1 induces G0/G1 phase arrest and mitochondria-dependent apoptosis in cisplatin-resistant human oral cancer CAR cells. Biomedicine (Taipei) (2017) 0.77
Enhancer-Mediated Oncogenic Function of the Menin Tumor Suppressor in Breast Cancer. Cell Rep (2017) 0.77
Vav1: A Dr. Jekyll and Mr. Hyde protein - good for the hematopoietic system, bad for cancer. Oncotarget (2015) 0.77
Compounds identified by virtual docking to a tetrameric EGFR extracellular domain can modulate Grb2 internalization. BMC Cancer (2015) 0.76
Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer. BMC Cancer (2016) 0.75
The Rac GTPase in cancer: from old concepts to new paradigms. Cancer Res (2017) 0.75
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
Model-based analysis of ChIP-Seq (MACS). Genome Biol (2008) 51.63
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
TM4 microarray software suite. Methods Enzymol (2006) 13.78
BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res (2006) 10.36
Genetics and beyond--the transcriptome of human monocytes and disease susceptibility. PLoS One (2010) 7.48
Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer (2009) 5.89
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature (2012) 5.84
FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet (2010) 5.22
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet (2013) 4.03
Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet (2013) 3.96
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep (2013) 3.85
ChIPpeakAnno: a Bioconductor package to annotate ChIP-seq and ChIP-chip data. BMC Bioinformatics (2010) 3.47
Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics (2008) 3.24
Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res (2008) 2.27
Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology (1998) 2.18
Four enzymes cooperate to displace histone H1 during the first minute of hormonal gene activation. Genes Dev (2011) 1.97
A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese. Hum Mol Genet (2011) 1.91
Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res (1987) 1.78
MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. Cancer Res (1997) 1.74
Tyrosine phosphorylation mediates both activation and downmodulation of the biological activity of Vav. Mol Cell Biol (2000) 1.71
Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer. Acta Oncol (2007) 1.58
Identification of pathway-selective estrogen receptor ligands that inhibit NF-kappaB transcriptional activity. Proc Natl Acad Sci U S A (2005) 1.50
Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. Clin Cancer Res (2003) 1.50
Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor. Cancer Res (2008) 1.44
Vav3 mediates receptor protein tyrosine kinase signaling, regulates GTPase activity, modulates cell morphology, and induces cell transformation. Mol Cell Biol (2000) 1.40
Vav1 regulates phospholipase cgamma activation and calcium responses in mast cells. Mol Cell Biol (2001) 1.38
Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture. Eur J Cancer Clin Oncol (1987) 1.38
Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer (2010) 1.31
Mapping DNA target sites of chromatin proteins in vivo by formaldehyde crosslinking. Methods Mol Biol (1999) 1.30
Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway. Cancer Res (2012) 1.30
Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res Treat (1994) 1.27
Coupling of receptor conformation and ligand orientation determine graded activity. Nat Chem Biol (2010) 1.25
Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. J Steroid Biochem Mol Biol (2002) 1.23
Selection and characterization of a breast cancer cell line resistant to the antiestrogen LY 117018. Endocrinology (1985) 1.20
Screensaver: an open source lab information management system (LIMS) for high throughput screening facilities. BMC Bioinformatics (2010) 1.19
The rho exchange factors vav2 and vav3 control a lung metastasis-specific transcriptional program in breast cancer cells. Sci Signal (2012) 1.17
Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. J Steroid Biochem Mol Biol (2007) 1.15
Vav3 oncogene activates estrogen receptor and its overexpression may be involved in human breast cancer. BMC Cancer (2008) 1.14
Cyclic GMP induced apoptosis via protein kinase G in oestrogen receptor-positive and -negative breast cancer cell lines. FEBS J (2011) 1.12
Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer. Endocr Relat Cancer (2011) 1.12
Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit. Breast Cancer Res Treat (2012) 1.10
Validation of an empirical RNA-ligand scoring function for fast flexible docking using Ribodock. J Comput Aided Mol Des (2004) 1.08
Vav3-rac1 signaling regulates prostate cancer metastasis with elevated Vav3 expression correlating with prostate cancer progression and posttreatment recurrence. Cancer Res (2012) 1.07
Estrogen receptor-alpha phosphorylation at serine 305, nuclear p21-activated kinase 1 expression, and response to tamoxifen in postmenopausal breast cancer. Clin Cancer Res (2010) 1.05
Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid arthritis. J Med Chem (2004) 1.03
Biological reprogramming in acquired resistance to endocrine therapy of breast cancer. Oncogene (2010) 1.01
A novel nuclear role for the Vav3 nucleotide exchange factor in androgen receptor coactivation in prostate cancer. Oncogene (2011) 1.00
Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival. Mol Endocrinol (2012) 1.00
Vav1 is a component of transcriptionally active complexes. J Exp Med (2002) 0.98
The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials. Breast Cancer Res (2013) 0.97
Inhibition of the Rho GTPase, Rac1, decreases estrogen receptor levels and is a novel therapeutic strategy in breast cancer. Endocr Relat Cancer (2011) 0.95
Collation and data-mining of literature bioactivity data for drug discovery. Biochem Soc Trans (2011) 0.94
Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: where are we now and where are we going? Crit Rev Oncol Hematol (2012) 0.93
Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1. Breast Cancer Res (2011) 0.92
Vav3 is regulated during the cell cycle and effects cell division. Proc Natl Acad Sci U S A (2002) 0.91
New and translational perspectives of oestrogen deprivation in breast cancer. Mol Cell Endocrinol (2011) 0.87
Novel interaction between the co-chaperone Cdc37 and Rho GTPase exchange factor Vav3 promotes androgen receptor activity and prostate cancer growth. J Biol Chem (2012) 0.86
Understanding resistance to endocrine agents: molecular mechanisms and potential for intervention. Clin Breast Cancer (2010) 0.86
Endocrine resistance in breast cancer: new roles for ErbB3 and ErbB4. Breast Cancer Res (2011) 0.82
Novel concepts for the chemoprevention of breast cancer through aromatase inhibition. Endocr Relat Cancer (2006) 0.78
Molecular modeling of estrogen receptor using molecular operating environment. Biochem Mol Biol Educ (2007) 0.78
A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 85.39
Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet (2002) 40.37
Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet (2009) 26.09
Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet (2008) 25.83
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet (2008) 20.66
International network of cancer genome projects. Nature (2010) 20.35
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell (2005) 18.20
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89
Genome-wide detection and characterization of positive selection in human populations. Nature (2007) 17.27
Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A (2005) 15.46
Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet (2007) 15.27
The Polycomb group protein EZH2 directly controls DNA methylation. Nature (2005) 13.67
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet (2009) 12.44
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
Rapid "open-source" engineering of customized zinc-finger nucleases for highly efficient gene modification. Mol Cell (2008) 11.24
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell (2007) 11.21
Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat Genet (2008) 9.39
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature (2012) 9.39
A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature (2004) 8.67
SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations. Nat Genet (2008) 8.63
Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet (2005) 8.45
Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet (2009) 8.11
A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell (2004) 8.06
Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A (2006) 8.01
Adjuvant docetaxel for node-positive breast cancer. N Engl J Med (2005) 8.00
Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet (2003) 7.98
Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
Demethylation of H3K27 regulates polycomb recruitment and H2A ubiquitination. Science (2007) 7.41
Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics (2011) 7.38
Epigenetic modifications and human disease. Nat Biotechnol (2010) 7.29
A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A (2008) 7.14
Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res (2002) 7.09
Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet (2003) 7.04
Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat Genet (2008) 6.75
Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet (2002) 6.46
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A (2003) 6.35
The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J Cell Sci (2003) 6.24
Heterozygous TGFBR2 mutations in Marfan syndrome. Nat Genet (2004) 6.15
Cancer epigenetics reaches mainstream oncology. Nat Med (2011) 5.83
Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res (2007) 5.62
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol (2010) 5.50
Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease. Hum Mol Genet (2005) 5.35
Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA (2009) 5.32
MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA (2002) 5.29
A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet (2009) 5.29
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A (2006) 5.23
Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion. Nat Genet (2007) 4.99
Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet (2012) 4.84
Statistical methods for analysis of high-throughput RNA interference screens. Nat Methods (2009) 4.76
SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol (2004) 4.72
Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis. PLoS Genet (2009) 4.71
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet (2012) 4.63
An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. Nat Genet (2003) 4.61
Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med (2011) 4.51
DNA methyltransferases control telomere length and telomere recombination in mammalian cells. Nat Cell Biol (2006) 4.38
A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet (2012) 4.37
Genome-wide association study of hematological and biochemical traits in a Japanese population. Nat Genet (2010) 4.36
A functional polymorphism in the 5' UTR of GDF5 is associated with susceptibility to osteoarthritis. Nat Genet (2007) 4.31
Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem (2004) 4.31
A role for RNAi in the selective correction of DNA methylation defects. Science (2009) 4.30
Distinct DNA methylomes of newborns and centenarians. Proc Natl Acad Sci U S A (2012) 4.26
Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis. Nat Cell Biol (2003) 4.25
Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21
Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol Cell Biol (2004) 4.15
Susceptibility to coronary artery disease and diabetes is encoded by distinct, tightly linked SNPs in the ANRIL locus on chromosome 9p. Hum Mol Genet (2007) 4.09
An ADIOL-ERβ-CtBP transrepression pathway negatively regulates microglia-mediated inflammation. Cell (2011) 4.04
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol (2005) 4.04
MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. Cell (2012) 4.01
HJURP is a cell-cycle-dependent maintenance and deposition factor of CENP-A at centromeres. Cell (2009) 3.94
Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration): a meta-analysis of genome-wide association studies. Lancet Neurol (2012) 3.93
Lipid-related markers and cardiovascular disease prediction. JAMA (2012) 3.91
Retracted A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat Genet (2009) 3.88
Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res (2009) 3.81
Seven new loci associated with age-related macular degeneration. Nat Genet (2013) 3.81
Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N Engl J Med (2011) 3.80
Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet (2012) 3.71
Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res (2008) 3.70
Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ (2011) 3.65
The Spemann organizer gene, Goosecoid, promotes tumor metastasis. Proc Natl Acad Sci U S A (2006) 3.64
IntOGen: integration and data mining of multidimensional oncogenomic data. Nat Methods (2010) 3.63
Recognition of hemi-methylated DNA by the SRA protein UHRF1 by a base-flipping mechanism. Nature (2008) 3.62
Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case-control study. Lancet Oncol (2008) 3.60
Utility of TICS-M for the assessment of cognitive function in older adults. Int J Geriatr Psychiatry (2003) 3.56
Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res (2009) 3.52
PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res (2007) 3.51
DNA methylation and cancer. Adv Genet (2010) 3.50
Epigenetics and aging: the targets and the marks. Trends Genet (2007) 3.44
Identification of a putative intestinal stem cell and early lineage marker; musashi-1. Differentiation (2003) 3.41
Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nat Genet (2011) 3.40
A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity. Cell (2005) 3.35